Related Experiment Video
Updated: Jul 15, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
A new putative target for antisense gene therapy of glioma: glycogen synthase
Maryvonne Ardourel1, Marion Blin, Jean-Luc Moret
1Neurobiology Laboratory, Orleans, France.
Abstract:
The treatment of malignant brain gliomas remains a challenge, despite the availability of the classical triad of surgery, radiotherapy, and chemotherapy. There is thus the need for investigations into other forms of treatment strategies, such as gene therapy. Using antisense technology we have targeted glycogen metabolism, since malignant astrocytes present a high content of glycogen. In vitro rat C6‑glioma cells, transfected with antisense glycogen synthase (C6‑AS cells) exhibited a decreased expression of glycogen synthase and reduced activity of glycogen synthesis, along with attenuated invasiveness. In vivo tumors induced by C6‑AS cells in nude mice exhibited a significant reduction in tumor growth compared with controls. This reduction could be mediated by the induction of MCH‑I expression. The inhibition of glycogen synthesis by antisense glycogen synthase validates a putative target and a new approach for further study to advance the much‑needed efficacy of intervention strategies for malignant gliomas.
Insights
Investigating gene therapy for malignant brain gliomas, this study targeted glycogen metabolism in glioma cells using antisense glycogen synthase. This approach reduced tumor growth and invasiveness, offering a promising new strategy for glioma treatment.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Gene Therapy
Background:
- Malignant brain gliomas are challenging to treat with current therapies.
- Malignant astrocytes exhibit high glycogen content, suggesting a metabolic vulnerability.
- Novel therapeutic strategies, including gene therapy, are needed for gliomas.
Purpose of the Study:
- To investigate the potential of targeting glycogen metabolism in malignant gliomas using antisense technology.
- To evaluate the efficacy of inhibiting glycogen synthesis in glioma cells both in vitro and in vivo.
Main Methods:
- Utilized antisense technology to transfect rat C6-glioma cells, creating C6-AS cells with reduced glycogen synthase expression.
- Assessed in vitro effects on glycogen synthesis, cell invasiveness, and in vivo tumor growth in nude mice.
Main Results:
- C6-AS cells showed decreased glycogen synthase expression and reduced glycogen synthesis activity.
- In vitro studies demonstrated attenuated invasiveness of C6-AS cells.
- In vivo, tumors induced by C6-AS cells exhibited significantly reduced growth compared to controls.
- Tumor growth reduction may be linked to the induction of MCH-I expression.
Conclusions:
- Inhibition of glycogen synthesis via antisense glycogen synthase is a validated target for malignant gliomas.
- This approach represents a novel strategy for improving glioma treatment efficacy.
- Further research is warranted to advance this gene therapy approach for malignant gliomas.
